{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:25:39Z","timestamp":1791588339718,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bjoms.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.bjoms.2021.03.006","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T12:27:37Z","timestamp":1616588857000},"page":"e216-e230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy?"],"prefix":"10.1016","volume":"60","author":[{"given":"R.","family":"Sacco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7879-8815","authenticated-orcid":false,"given":"J.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Calasans-Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-023X","authenticated-orcid":false,"given":"J.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjoms.2021.03.006_bib0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1756-8722-3-26","article-title":"Angiogenesis inhibitors in the treatment of prostate cancer","volume":"3","author":"Hwang","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0015","first-page":"37","article-title":"Antiangiogenic therapeutic drugs for treatment of human cancer","volume":"4","author":"Wu","year":"2008","journal-title":"J Cancer Mol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0020","unstructured":"FDA. Avastin (bevacizumab) Information. Oct 25 2020. Available from URL: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125085s301lbl.pdf last accessed 25 October 2021."},{"key":"10.1016\/j.bjoms.2021.03.006_bib0025","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2014.29.1.1","article-title":"Antiangiogenesis therapy: an update after the first decade","volume":"29","author":"De Falco","year":"2014","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0035","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/phar.1147","article-title":"Antiangiogenic therapy for cancer: an update","volume":"32","author":"Al-Husein","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pharmthera.2016.06.001","article-title":"Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as antiangiogenic agents","volume":"164","author":"Falcon","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0045","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3892\/or.2013.2948","article-title":"Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma","volume":"31","author":"Moriya","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0050","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":"Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus","volume":"66","author":"Del Bufalo","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000262450","article-title":"Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review","volume":"56","author":"Boehm","year":"2010","journal-title":"Gerontology"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0060","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ad.2014.02.010","article-title":"Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab","volume":"105","author":"Ara","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0070","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0075","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0080","first-page":"1793","article-title":"Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease","volume":"33","author":"Sivolella","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","article-title":"Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts","volume":"473","author":"Nakagawa","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2005.07.145","article-title":"Vascular endothelial growth factor receptors in osteoclast differentiation and function","volume":"335","author":"Aldridge","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0095","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11914-018-0474-4","article-title":"Current understanding of the pathophysiology of osteonecrosis of the jaw","volume":"16","author":"Chang","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ctrv.2015.04.007","article-title":"Drug induced osteonecrosis of the jaw","volume":"41","author":"Hamadeh","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0110","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cden.2013.12.006","article-title":"Antiresorptive drug-related osteonecrosis of the jaw","volume":"58","author":"Uyanne","year":"2014","journal-title":"Dent Clin North Am"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0120","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","article-title":"Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review","volume":"44","author":"Fliefel","year":"2015","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0125","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s10103-016-1929-4","article-title":"Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review","volume":"31","author":"Weber","year":"2016","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.joms.2010.07.014","article-title":"Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study","volume":"69","author":"Pautke","year":"2011","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0135","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdn630","article-title":"Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome","volume":"20","author":"Van den Wyngaert","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0140","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.jcms.2016.08.001","article-title":"Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws","volume":"44","author":"Klingelh\u00f6ffer","year":"2016","journal-title":"J Craniomaxillofac Surg"},{"issue":"Suppl 5","key":"10.1016\/j.bjoms.2021.03.006_bib0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.joms.2009.01.006","article-title":"The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Carlson","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0150","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/odi.12764","article-title":"Medication-related osteonecrosis of the jaw: surgical or non-surgical treatment?","volume":"24","author":"Favia","year":"2018","journal-title":"Oral Dis"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0155","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8071579","article-title":"Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-na\u00efve patient: a comprehensive review of the literature","volume":"2018","author":"Pimolbutr","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0160","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0165","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011)","year":"2011"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0170","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0175","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document","volume":"89","author":"Riley","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0180","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PRS.0b013e3182195826","article-title":"The level of evidence pyramid: indicating levels of evidence in plastic and reconstructive surgery articles","volume":"128","author":"Sullivan","year":"2011","journal-title":"Plast Reconst Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0190","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.bjoms.2021.03.006_bib0195","article-title":"Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma","volume":"102","author":"Garuti","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0200","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10006-020-00851-w","article-title":"Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a patient receiving Bemcentinib\u2014a case report","volume":"24","author":"Bumm","year":"2020","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0205","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","article-title":"Sunitinib related osteonecrosis of jaw: a case report","volume":"113","author":"Fleissig","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/diseases6030079","article-title":"\u201cHoles\u201d in the jaw\u2014a report of two cases of periapical actinomycosis","volume":"6","author":"Ayoade","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/dj4040039","article-title":"Delayed diagnosis of osteonecrosis of the jaw (ONJ) associated with bevacizumab therapy in colorectal cancer patients: report of two cases","volume":"4","author":"Erovigni","year":"2016","journal-title":"Dent J (Basel)"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0220","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-007284","article-title":"Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process","volume":"2012","author":"Bettini","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.oooo.2017.10.010","article-title":"Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort","volume":"125","author":"Abel Mahedi Mohamed","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0230","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/687043","article-title":"Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature","volume":"2010","author":"Agostino","year":"2010","journal-title":"Adv Urol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0235","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bjoms.2019.05.017","article-title":"Everolimus-induced osteonecrosis of the jaw in the absence of bisphosphonates: a case report","volume":"57","author":"Akkach","year":"2019","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0240","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.oooo.2017.08.003","article-title":"Axitinib-related osteonecrosis of the jaw","volume":"124","author":"Patel","year":"2017","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0245","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0250","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3892\/mco.2016.1100","article-title":"Osteonecrosis of the jaw associated with everolimus: a case report","volume":"6","author":"Yamamoto","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0255","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ors.12153","article-title":"Osteonecrosis of the mandible in a patient with lung adenocarcinoma undergoing antiangiogenic therapy with bevacizumab","volume":"9","author":"Tzermpos","year":"2016","journal-title":"Oral Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0260","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/j.oooo.2018.05.008","article-title":"Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review","volume":"126","author":"Won","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0265","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","article-title":"Osteonecrosis of the mandible associated with bevacizumab therapy","volume":"115","author":"Santos-Silva","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"Suppl 2","key":"10.1016\/j.bjoms.2021.03.006_bib0270","article-title":"Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district","volume":"102","author":"Ponzetti","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0275","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10006-012-0379-9","article-title":"Osteonecrosis of the mandible due to antiangiogenic agent, bevacizumab","volume":"17","author":"Pakosch","year":"2013","journal-title":"Oral and Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0280","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tripleo.2011.08.024","article-title":"Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications","volume":"113","author":"Nicolatou-Galitis","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0285","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.21037\/jgo.2016.05.07","article-title":"Osteonecrosis of the jaw associated with ziv-aflibercept","volume":"7","author":"Mawardi","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0290","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2478\/amb-2019-0019","article-title":"Osteonecrosis of the jaws in patients receiving antiangiogenic drugs and chemotherapeutics: literature review and case reports","volume":"46","author":"Mihaylova","year":"2019","journal-title":"Acta Medica Bulgarica"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0295","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40729-019-0188-0","article-title":"A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants","volume":"5","author":"Maluf","year":"2019","journal-title":"Int J Implant Dent"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0300","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/adj.12254","article-title":"Osteonecrosis of the jaw in a patient receiving cabozantinib","volume":"60","author":"Marino","year":"2015","journal-title":"Aust Dent J"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0305","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.joms.2012.03.022","article-title":"Unusual bevacizumab-related complication of an oral infection","volume":"71","author":"Magremanne","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0315","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.joms.2011.02.104","article-title":"Osteonecrosis after administration of intravitreous bevacizumab","volume":"70","author":"Hopp","year":"2012","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0320","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omsc.2017.03.001","article-title":"Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient","volume":"3","author":"Jung","year":"2017","journal-title":"Oral Maxillofac Surg Cases"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0325","first-page":"655","article-title":"A case of osteonecrosis of the jaw during treatment by bevacizumab for sigmoid colon cancer","volume":"110","author":"Sato","year":"2013","journal-title":"J Jpn Soc Gastroenterol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0330","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcms.2013.05.014","article-title":"Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab","volume":"42","author":"Allegra","year":"2014","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0335","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw002","article-title":"Regorafenib also can cause osteonecrosis of the jaw","volume":"108","author":"Antonuzzo","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0340","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/039463201202500328","article-title":"Osteonecrosis of the jaws and bevacizumab therapy: a case report","volume":"25","author":"Brunamonti Binello","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0345","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit","volume":"48","author":"Di\u015fel","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0350","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.12659\/AJCR.905355","article-title":"A case of osteonecrosis of the jaw in a patient with Crohn\u2019s disease treated with infliximab","volume":"18","author":"Favia","year":"2017","journal-title":"Am J Case Rep"},{"issue":"Suppl 2","key":"10.1016\/j.bjoms.2021.03.006_bib0355","first-page":"31","article-title":"Bevacizumab-related osteonecrosis of jaw in a rectal cancer patient never treated with bisphosphonates","volume":"5","author":"Fusco","year":"2014","journal-title":"Ann Stomatol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0360","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0365","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.arbres.2012.01.007","article-title":"Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab","volume":"48","author":"Katsenos","year":"2012","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0370","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.ijom.2019.07.010","article-title":"Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib","volume":"48","author":"Mauceri","year":"2019","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0375","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.1200\/jco.2008.26.15_suppl.9588","article-title":"Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and\/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center. (MSKCC)","volume":"26","author":"McArthur","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0380","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/039463200902200429","article-title":"Bevacizumab-related osteneocrosis of the jaw","volume":"22","author":"Serra","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0385","first-page":"40","article-title":"Mandibular osteonecrosis related to cabozantinib","author":"Tempia Valenta","year":"2012","journal-title":"Abstracts of the 11th Biennial Congress of the European Association of Oral Medicine"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0390","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0395","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00432-014-1853-6","article-title":"Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients","volume":"141","author":"Gabbert","year":"2015","journal-title":"Cancer Res Clin Oncol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0400","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","article-title":"Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment","volume":"40","author":"Otto","year":"2012","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0405","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","article-title":"Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review","volume":"44","author":"Fliefel","year":"2015","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0410","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tripleo.2010.02.020","article-title":"Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study","volume":"110","author":"Scoletta","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.bjoms.2021.03.006_bib0415","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0266435621001133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0266435621001133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:31:03Z","timestamp":1759419063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0266435621001133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0266435621001133"],"URL":"https:\/\/doi.org\/10.1016\/j.bjoms.2021.03.006","relation":{},"ISSN":["0266-4356"],"issn-type":[{"value":"0266-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy?","name":"articletitle","label":"Article Title"},{"value":"British Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjoms.2021.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}